Optimata Granted Patent for Modeling Thrombopoiesis.Wide Applications for Cancer Drug Development RAMAT GAN Ramat Gan (rä`mät gän), city (1994 pop. 122,200), W central Israel, adjacent to Tel Aviv. Founded in 1921, Ramat Gan is an important industrial center. Food processing is the chief industry; construction materials are also made there. , Israel -- Optimata Ltd. announced today that it has been granted U.S. Patent 7,133,814 for inventing a system that models the development of thrombopoiesis thrombopoiesis /throm·bo·poi·e·sis/ (-poi-e´sis) 1. thrombogenesis. 2. thrombocytopoiesis.thrombopoiet´ic throm·bo·poi·e·sis n. 1. in humans. The invention enables simulating the thrombopoietic process in virtual patients where different therapies are applied. Thrombocytpoienia is a toxic condition that often occurs during cancer treatment. The Optimata invention can be applied to optimize the development of new drugs as well to optimize and personalize per·son·al·ize tr.v. per·son·al·ized, per·son·al·iz·ing, per·son·al·iz·es 1. To take (a general remark or characterization) in a personal manner. 2. To attribute human or personal qualities to; personify. the use of existing drugs. "This patent reinforces Optimata's leadership position in the field of predictive toxicity. By using the predictive powers of Optimata's Virtual Patient Engine, drug developers have the benefit of an 'early warning system' for the toxic consequences of thrombocytopenia Thrombocytopenia Definition Thrombocytopenia is an abnormal drop in the number of blood cells involved in forming blood clots. These cells are called platelets. ," said Guy Malchi, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Optimata. Optimata's Virtual Patient technology is currently playing a crucial role in drug development programs carried out by major pharmaceutical companies including Eli Lilly Eli Lilly can refer to:
In addition, together with Cancer research UK, the company recently announced the successful results of a clinical study for the prediction of individualized in·di·vid·u·al·ize tr.v. in·di·vid·u·al·ized, in·di·vid·u·al·iz·ing, in·di·vid·u·al·iz·es 1. To give individuality to. 2. To consider or treat individually; particularize. 3. breast cancer patient response to chemotherapy drugs. The study showed that the prediction accuracy of the Virtual Cancer Patient was 70 percent compared to the current prediction accuracy of oncologists which is estimated to be 25-30 percent. "The registration of this patent, combined with the increasing commercial validation of our Virtual Patient technologies, paves the way for our new program aimed at re-purposing discontinued oncology compounds," said Zvia Agur, Founder and Chairperson. About Optimata Optimata Ltd. is a science-based, interdisciplinary company, dedicated to the development of predictive biosimulation technologies - Virtual Patient Engines. Founded by Prof. Zvia Agur, a world-renowned biomathematician who has pioneered methods of using computer modeling for optimizing treatment protocols in cancer and pathogenic path·o·gen·ic or path·o·ge·net·ic adj. 1. Having the capability to cause disease. 2. Producing disease. 3. Relating to pathogenesis. diseases, Optimata offers a rational approach for the selection of patient populations and the optimization of drug scheduling and dosage. Optimata's technology is based on a computer-generated method of accurately predicting how individual patients or patient populations will respond to a compound. The technology combines computer models of human physiology Human physiology is the science of the mechanical, physical, and biochemical functions of humans in good health, their organs, and the cells of which they are composed. The principal level of focus of physiology is at the level of organs and systems. , specific diseases and the therapeutic impact of a compound. The in-silico technology enables drug developers to conduct experiments at an unprecedented scale, enabling an unlimited number of "virtual trials" to be carried out on an almost infinite combination of dosages, treatment schedules and patient population characteristics. Major pharmaceutical company clients include Eli Lilly. In addition to the trial described above, the company is currently completing a bio-simulation clinical trial on individualized breast cancer therapy in collaboration with Soroka University Medical Center in Israel. For more information about Optimata visit www.optimata.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion